| (*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| (*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| (R*)- miniCHOP Therapy - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| (R*)-DHAP Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| (R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Abemaciclib Therapy. NCCP National SACT Regimen. HSE. |
1 |
12 |
| Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Adcetris (brentuximab vedotin) [package insert]. FDA. |
2 |
2 |
| Adcetris (brentuximab vedotin) [product information]. EMA. |
4 |
4 |
| Afatinib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Afinitor (everolimus) [package insert]. FDA. |
3 |
7 |
| Afinitor (everolimus) [product information]. EMA. |
1 |
3 |
| Akeega (abiraterone acetate and niraparib) [package insert]. FDA. |
1 |
4 |
| Akeega (abiraterone acetate and niraparib) [product information]. EMA. |
1 |
4 |
| Alecensa (alectinib) [package insert]. FDA. |
1 |
2 |
| Alecensa (alectinib) [product information]. EMA. |
3 |
3 |
| Alectinib Monotherapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Alunbrig (brigatinib) [package insert]. FDA. |
1 |
1 |
| Alunbrig (brigatinib) [product information]. EMA. |
2 |
2 |
| Anastrozole Monotherapy. NCCP National SACT Regimen. HSE. |
3 |
9 |
| Arimidex (anastrozole) [summary of product characteristics]. HPRA. |
3 |
9 |
| Aromasin (exemestane) [summary of product characteristics]. HPRA. |
1 |
1 |
| Asciminib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE. |
4 |
6 |
| Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE. |
3 |
4 |
| Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE. |
4 |
6 |
| Atezolizumab and nab-PACLitaxel Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Augtyro (repotrectinib) [package insert]. FDA. |
2 |
4 |
| Avastin (bevacizumab) [product information]. EMA. |
1 |
2 |
| Ayvakit (avapritinib) [package insert]. FDA. |
1 |
1 |
| Ayvakyt (avapritinib) [product information]. EMA. |
1 |
1 |
| Balversa (erdafitinib) [package insert]. FDA. |
1 |
5 |
| Balversa (erdafitinib) [product information]. EMA. |
1 |
8 |
| Besponsa (inotuzumab ozogamicin) [package insert]. FDA. |
1 |
1 |
| Besponsa (inotuzumab ozogamicin) [product information]. EMA. |
1 |
2 |
| Bevacizumab 10mg/kg - 14 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Bizengri (zenocutuzumab-zbco) [package insert]. FDA. |
2 |
2 |
| Blinatumomab Paediatric Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Blinatumomab Therapy (ALL with MRD >= 0.1%). NCCP National SACT Regimen. HSE. |
1 |
1 |
| Blinatumomab Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Blincyto (blinatumomab) [package insert]. FDA. |
2 |
3 |
| Blincyto (blinatumomab) [product information]. EMA. |
4 |
5 |
| Bosulif (bosutinib) [package insert]. FDA. |
1 |
3 |
| Bosulif (bosutinib) [product information]. EMA. |
2 |
2 |
| Bosutinib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Braftovi (encorafenib) [package insert]. FDA. |
4 |
5 |
| Braftovi (encorafenib) [product information]. EMA. |
3 |
4 |
| Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE. |
4 |
4 |
| Brentuximab vedotin and Bendamustine Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Brentuximab vedotin and ICE Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP). NCCP National SACT Regimen. HSE. |
1 |
1 |
| Brigatinib Therapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy - Triple Negative Breast Cancer Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Capecitabine Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Caprelsa (vandetanib) [product information]. EMA. |
1 |
1 |
| Ceritinib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cetuximab (14 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cetuximab (14 days) and Irinotecan (14 days) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cetuximab (7 days) and Irinotecan (14 days) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cetuximab Therapy-7 day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cobimetinib and Vemurafenib Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Cotellic (cobimetinib) [package insert]. FDA. |
1 |
2 |
| Cotellic (cobimetinib) [product information]. EMA. |
1 |
2 |
| Crizotinib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Cyramza (ramucirumab) [package insert]. FDA. |
1 |
2 |
| Cyramza (ramucirumab) [product information]. EMA. |
1 |
1 |
| DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH). NCCP National SACT Regimen. HSE. |
2 |
2 |
| Dabrafenib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Dacomitinib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH) Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH). NCCP National SACT Regimen. HSE. |
2 |
2 |
| Durvalumab Monotherapy 10mg/kg - 14 Day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Durvalumab Monotherapy 1500 mg - 28 day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA. |
1 |
3 |
| Encorafenib and Binimetinib Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Enhertu (trastuzumab deruxtecan) [package insert]. FDA. |
5 |
5 |
| Enhertu (trastuzumab deruxtecan) [product information]. EMA. |
4 |
7 |
| Ensacove (ensartinib) [package insert]. FDA. |
1 |
1 |
| Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Entrectinib Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Erbitux (cetuximab) [package insert]. FDA. |
4 |
4 |
| Erbitux (cetuximab) [product information]. EMA. |
3 |
3 |
| Erlotinib Therapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Everolimus and Exemestane Therapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Exemestane Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Exkivity (mobocertinib) [package insert]. FDA. |
1 |
1 |
| Faslodex (fulvestrant) [package insert]. FDA. |
4 |
15 |
| Faslodex (fulvestrant) [product information]. EMA. |
2 |
4 |
| Femara (letrozole) [summary of product characteristics]. HPRA. |
4 |
12 |
| Fulvestrant Therapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Gavreto (pralsetinib) [package insert]. FDA. |
2 |
2 |
| Gavreto (pralsetinib) [product information]. EMA. |
1 |
1 |
| Gefitinib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction). NCCP National SACT Regimen. HSE. |
1 |
1 |
| Gilotrif (afatinib) [package insert]. FDA. |
1 |
1 |
| Giotrif (afatinib) [product information]. EMA. |
1 |
1 |
| Gleevec (imatinib) [package insert]. FDA. |
7 |
12 |
| Glivec (imatinib) [product information]. EMA. |
8 |
11 |
| Herceptin (trastuzumab) [package insert]. FDA. |
2 |
2 |
| Herceptin (trastuzumab) [product information]. EMA. |
9 |
22 |
| Ibrance (palbociclib) [package insert]. FDA. |
2 |
6 |
| Ibrance (palbociclib) [product information]. EMA. |
2 |
6 |
| Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Iclusig (ponatinib) [package insert]. FDA. |
3 |
3 |
| Iclusig (ponatinib) [product information]. EMA. |
2 |
3 |
| Idelalisib and Ofatumumab Therapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Idhifa (enasidenib) [package insert]. FDA. |
1 |
9 |
| Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Imfinzi (durvalumab) [package insert]. FDA. |
3 |
10 |
| Imfinzi (durvalumab) [product information]. EMA. |
3 |
4 |
| Imjudo (tremelimumab) [product information]. EMA. |
1 |
1 |
| Imjudo (tremelimumab-actl) [package insert]. FDA. |
1 |
5 |
| Inotuzumab Ozogamicin Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Iressa (gefitinib) [package insert]. FDA. |
1 |
2 |
| Iressa (gefitinib) [product information]. EMA. |
1 |
1 |
| Itovebi (inavolisib) [package insert]. FDA. |
1 |
3 |
| Jemperli (dostarlimab) [package insert]. FDA. |
3 |
4 |
| Jemperli (dostarlimab) [product information]. EMA. |
2 |
4 |
| KG. EMA. |
2 |
5 |
| Kadcyla (ado-trastuzumab emtansine) [package insert]. FDA. |
1 |
2 |
| Kadcyla (trastuzumab emtansine) [product information]. EMA. |
2 |
4 |
| Keytruda (pembrolizumab) [package insert]. FDA. |
16 |
32 |
| Keytruda (pembrolizumab) [product information]. EMA. |
15 |
35 |
| Kisqali (ribociclib) [package insert]. FDA. |
3 |
15 |
| Kisqali (ribociclib) [product information]. EMA. |
1 |
6 |
| Krazati (adagrasib) [package insert]. FDA. |
2 |
2 |
| Krazati (adagrasib) [product information]. EMA. |
1 |
1 |
| Lapatinib and Capecitabine Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Larotrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Larotrectinib Monotherapy - Paediatric. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Lazcluze (lazertinib) [package insert]. FDA. |
1 |
2 |
| Letrozole Monotherapy. NCCP National SACT Regimen. HSE. |
4 |
12 |
| Libtayo (cemiplimab) [package insert]. FDA. |
2 |
2 |
| Libtayo (cemiplimab) [product information]. EMA. |
2 |
2 |
| Lorbrena (lorlatinib) [package insert]. FDA. |
1 |
1 |
| Lorlatinib Therapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Lorviqua (lorlatinib) [product information]. EMA. |
2 |
2 |
| Lumakras (sotorasib) [package insert]. FDA. |
1 |
1 |
| Lumykras (sotorasib) [product information]. EMA. |
1 |
1 |
| Lynparza (olaparib) [package insert]. FDA. |
6 |
81 |
| Lynparza (olaparib) [product information]. EMA. |
7 |
38 |
| Lytgobi (futibatinib) [package insert]. FDA. |
1 |
1 |
| Lytgobi (futibatinib) [product information]. EMA. |
1 |
2 |
| MabThera (rituximab) [product information]. EMA. |
2 |
5 |
| Margenza (margetuximab-cmkb) [package insert]. FDA. |
1 |
4 |
| Mekinist (trametinib) [package insert]. FDA. |
6 |
8 |
| Mekinist (trametinib) [product information]. EMA. |
3 |
8 |
| Mektovi (binimetinib) [package insert]. FDA. |
2 |
3 |
| Mektovi (binimetinib) [product information]. EMA. |
2 |
3 |
| Midostaurin Maintenance Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Midostaurin, DAUNOrubicin and Cytarabine Induction Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA. |
1 |
2 |
| Mylotarg (gemtuzumab ozogamicin) [product information]. EMA. |
1 |
1 |
| Neratinib Therapy. NCCP National SACT Regimen. HSE. |
1 |
6 |
| Nerlynx (neratinib) [package insert]. FDA. |
2 |
2 |
| Nerlynx (neratinib) [product information]. EMA. |
1 |
6 |
| Niraparib and Abiraterone acetate (Akeega) and prednisoLONE Therapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Nivolumab 360mg and Chemotherapy. NCCP National SACT Regimen. HSE. |
1 |
5 |
| Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Nivolumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Ojemda (tovorafenib) [package insert]. FDA. |
1 |
4 |
| Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE. |
3 |
28 |
| Olaparib (Tablet) and Bevacizumab Therapy. NCCP National SACT Regimen. HSE. |
1 |
14 |
| Opdivo (nivolumab) [package insert]. FDA. |
5 |
11 |
| Opdivo (nivolumab) [product information]. EMA. |
7 |
17 |
| Opdualag (relatlimab / nivolumab) [product information]. EMA. |
1 |
1 |
| Orserdu (elacestrant) [package insert]. FDA. |
1 |
1 |
| Orserdu (elacestrant) [product information]. EMA. |
1 |
1 |
| Osimertinib Monotherapy. NCCP National SACT Regimen. HSE. |
3 |
4 |
| PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks). NCCP National SACT Regimen. HSE. |
1 |
1 |
| PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| PONATinib Therapy. NCCP National SACT Regimen. HSE. |
2 |
3 |
| Palbociclib Therapy - 28 day. NCCP National SACT Regimen. HSE. |
2 |
6 |
| Panitumumab 6mg/kg Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Panitumumab 6mg/kg and FOLFIRI Therapy-14 day. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pemazyre (pemigatinib) [package insert]. FDA. |
2 |
3 |
| Pemazyre (pemigatinib) [product information]. EMA. |
1 |
2 |
| Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE. |
5 |
7 |
| Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE. |
5 |
5 |
| Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pembrolizumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Perjeta (pertuzumab) [package insert]. FDA. |
3 |
12 |
| Perjeta (pertuzumab) [product information]. EMA. |
3 |
8 |
| Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab and Trastuzumab Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. |
2 |
7 |
| Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab, Trastuzumab, and Vinorelbine. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Phesgo (pertuzumab / trastuzumab) [product information]. EMA. |
3 |
10 |
| Phesgo (pertuzumab and trastuzumab) [package insert]. FDA. |
3 |
12 |
| Piqray (alpelisib) [package insert]. FDA. |
1 |
3 |
| Piqray (alpelisib) [product information]. EMA. |
1 |
3 |
| R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Retevmo (selpercatinib) [package insert]. FDA. |
4 |
4 |
| Retsevmo (selpercatinib) [product information]. EMA. |
4 |
4 |
| Revlimid (lenalidomide) [package insert]. FDA. |
1 |
1 |
| Revlimid (lenalidomide) [product information]. EMA. |
1 |
1 |
| Revuforj (revumenib) [package insert]. FDA. |
1 |
4 |
| Rezlidhia (olutasidenib) [package insert]. FDA. |
1 |
5 |
| RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day. NCCP National SACT Regimen. HSE. |
1 |
2 |
| RiTUXimab 375 mg/m2 Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE. |
1 |
2 |
| RiTUXimab and Bendamustine Therapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Ribociclib Therapy - 28 day. NCCP National SACT Regimen. HSE. |
2 |
9 |
| Rituxan (rituximab) [package insert]. FDA. |
5 |
11 |
| Rozlytrek (entrectinib) [package insert]. FDA. |
2 |
4 |
| Rozlytrek (entrectinib) [product information]. EMA. |
2 |
4 |
| Rubraca (rucaparib) [package insert]. FDA. |
2 |
16 |
| Rybrevant (amivantamab) [product information]. EMA. |
2 |
2 |
| Rybrevant (amivantamab-vmjw) [package insert]. FDA. |
4 |
6 |
| Rydapt (midostaurin) [package insert]. FDA. |
1 |
10 |
| Rydapt (midostaurin) [product information]. EMA. |
1 |
1 |
| Sacituzumab Govitecan Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Scemblix (asciminib) [package insert]. FDA. |
3 |
4 |
| Scemblix (asciminib) [product information]. EMA. |
1 |
1 |
| Spexotras (trametinib) [product information]. EMA. |
2 |
2 |
| Sprycel (dasatinib [anhydrous]) [product information]. EMA. |
4 |
5 |
| Sprycel (dasatinib) [package insert]. FDA. |
2 |
8 |
| Tabrecta (capmatinib) [package insert]. FDA. |
1 |
2 |
| Tabrecta (capmatinib) [product information]. EMA. |
1 |
2 |
| Tafinlar (dabrafenib) [package insert]. FDA. |
7 |
9 |
| Tafinlar (dabrafenib) [product information]. EMA. |
3 |
8 |
| Tagrisso (osimertinib) [package insert]. FDA. |
3 |
11 |
| Tagrisso (osimertinib) [product information]. EMA. |
4 |
8 |
| Talazoparib Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Talzenna (talazoparib) [package insert]. FDA. |
2 |
26 |
| Talzenna (talazoparib) [product information]. EMA. |
1 |
2 |
| Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Tarceva (erlotinib) [package insert]. FDA. |
1 |
2 |
| Tarceva (erlotinib) [product information]. EMA. |
2 |
2 |
| Tasigna (nilotinib) [package insert]. FDA. |
1 |
4 |
| Tasigna (nilotinib) [product information]. EMA. |
3 |
3 |
| Taxotere (docetaxel) [product information]. EMA. |
1 |
2 |
| Tazverik (tazemetostat) [package insert]. FDA. |
1 |
7 |
| Tecentriq (atezolizumab) [package insert]. FDA. |
6 |
9 |
| Tecentriq (atezolizumab) [product information]. EMA. |
7 |
12 |
| Tepmetko (tepotinib) [package insert]. FDA. |
1 |
2 |
| Tepmetko (tepotinib) [product information]. EMA. |
1 |
2 |
| Tepotinib Therapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Tevimbra (tislelizumab) [product information]. EMA. |
1 |
2 |
| Tibsovo (ivosidenib) [package insert]. FDA. |
3 |
25 |
| Tibsovo (ivosidenib) [product information]. EMA. |
2 |
10 |
| Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE. |
2 |
4 |
| Trastuzumab (IV) Monotherapy - 21 days. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Trastuzumab (IV) Monotherapy - 7 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Trastuzumab Deruxtecan (Enhertu) Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Trastuzumab Emtansine (Kadcyla) - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE. |
4 |
5 |
| Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE. |
4 |
6 |
| Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA. |
1 |
5 |
| Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy. NCCP National SACT Regimen. HSE. |
2 |
2 |
| Trisenox (arsenic trioxide) [package insert]. FDA. |
1 |
2 |
| Trisenox (arsenic trioxide) [product information]. EMA. |
1 |
1 |
| Trodelvy (sacituzumab govitecan) [package insert]. FDA. |
2 |
4 |
| Trodelvy (sacituzumab govitecan) [product information]. EMA. |
2 |
4 |
| Truqap (capivasertib) [package insert]. FDA. |
1 |
21 |
| Truqap (capivasertib) [product information]. EMA. |
1 |
8 |
| Truseltiq (infigratinib) [package insert]. FDA. |
1 |
1 |
| Tukysa (tucatinib) [package insert]. FDA. |
1 |
1 |
| Tukysa (tucatinib) [product information]. EMA. |
1 |
1 |
| Tykerb (lapatinib) [package insert]. FDA. |
2 |
4 |
| Tyverb (lapatinib) [product information]. EMA. |
3 |
6 |
| Vandetanib Therapy. NCCP National SACT Regimen. HSE. |
1 |
1 |
| Vectibix (panitumumab) [package insert]. FDA. |
2 |
2 |
| Vectibix (panitumumab) [product information]. EMA. |
3 |
4 |
| Vemurafenib Monotherapy. NCCP National SACT Regimen. HSE. |
1 |
2 |
| Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf. NCCP National SACT Regimen. HSE. |
2 |
4 |
| Verzenio (abemaciclib) [package insert]. FDA. |
4 |
24 |
| Verzenios (abemaciclib) [product information]. EMA. |
2 |
12 |
| Vitrakvi (larotrectinib) [package insert]. FDA. |
1 |
3 |
| Vitrakvi (larotrectinib) [product information]. EMA. |
1 |
3 |
| Vizimpro (dacomitinib) [package insert]. FDA. |
1 |
2 |
| Vizimpro (dacomitinib) [product information]. EMA. |
1 |
1 |
| Voranigo (vorasidenib) [package insert]. FDA. |
1 |
20 |
| Vyloy (zolbetuximab) [package insert]. FDA. |
1 |
2 |
| Vyloy (zolbetuximab) [product information]. EMA. |
1 |
2 |
| Xalkori (crizotinib) [package insert]. FDA. |
3 |
4 |
| Xalkori (crizotinib) [product information]. EMA. |
5 |
5 |
| Xeloda (capecitabine) [package insert]. FDA. |
1 |
1 |
| Xospata (gilteritinib) [package insert]. FDA. |
1 |
8 |
| Xospata (gilteritinib) [product information]. EMA. |
1 |
2 |
| Yervoy (ipilimumab) [package insert]. FDA. |
3 |
6 |
| Yervoy (ipilimumab) [product information]. EMA. |
3 |
6 |
| Zanubrutinib Therapy. NCCP National SACT Regimen. HSE. |
1 |
3 |
| Zejula (niraparib) [package insert]. FDA. |
1 |
6 |
| Zelboraf (vemurafenib) [package insert]. FDA. |
2 |
3 |
| Zelboraf (vemurafenib) [product information]. EMA. |
1 |
2 |
| Ziihera (zanidatamab-hrii) [package insert]. FDA. |
1 |
3 |
| Zydelig (idelalisib) [product information]. EMA. |
1 |
3 |
| Zykadia (ceritinib) [package insert]. FDA. |
1 |
1 |
| Zykadia (ceritinib) [product information]. EMA. |
2 |
2 |
| riTUXimab (S/C 1400mg) Maintenance Therapy-56 day. NCCP National SACT Regimen. HSE. |
1 |
2 |
| riTUXimab (S/C 1400mg) Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE. |
1 |
2 |
| riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE. |
1 |
4 |
| riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days. NCCP National SACT Regimen. HSE. |
2 |
2 |